NLRP3 and head and neck squamous cell carcinoma: More recent studies have shown systemic pharmacologic inhibition of NLRP3 to increase effector CD8+ T cells and suppress both CD4+FoxP3+ regulatory T cells and CD11b+Ly6G+Ly6Clo PMN-MDSCs in a transgenic Tgfbr1/Pten 2ccKO model of head and neck squamous cell carcinoma [42].